NASDAQ:SLRN Acelyrin (SLRN) Stock Price, News & Analysis $4.24 -0.33 (-7.22%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.20▼$4.6850-Day Range$3.98▼$7.0652-Week Range$3.36▼$28.24Volume914,327 shsAverage Volume1.25 million shsMarket Capitalization$423.19 millionP/E RatioN/ADividend YieldN/APrice Target$10.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Acelyrin alerts: Email Address Acelyrin MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside155.5% Upside$10.83 Price TargetShort InterestBearish10.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$7 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.08) to ($2.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector565th out of 910 stocksPharmaceutical Preparations Industry260th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingAcelyrin has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAcelyrin has only been the subject of 4 research reports in the past 90 days.Read more about Acelyrin's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.80% of the float of Acelyrin has been sold short.Short Interest Ratio / Days to CoverAcelyrin has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Acelyrin has recently decreased by 4.02%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAcelyrin does not currently pay a dividend.Dividend GrowthAcelyrin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRN. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 8 people have searched for SLRN on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acelyrin insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7.00 in company stock.Percentage Held by Insiders13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acelyrin's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Acelyrin are expected to grow in the coming year, from ($3.08) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acelyrin is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acelyrin is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcelyrin has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acelyrin's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Acelyrin Stock (NASDAQ:SLRN)Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Read More SLRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRN Stock News HeadlinesAugust 22, 2024 | globenewswire.comACELYRIN, INC. to Participate in Upcoming Investor ConferencesAugust 20, 2024 | markets.businessinsider.comACELYRIN, INC.: Hold Rating Maintained Amid Strategic Pipeline Shift and Extended Cash RunwaySeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 16, 2024 | msn.comHC Wainwright & Co. Downgrades Acelyrin (SLRN)August 15, 2024 | marketwatch.comAcelyrin Shares Slide on Layoffs, Portfolio RefocusAugust 15, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on ACELYRIN, INC. (SLRN)August 15, 2024 | markets.businessinsider.comACELYRIN, INC. Maintains Hold Rating Amidst Mixed Clinical Results and Competitive Market ChallengesAugust 15, 2024 | msn.comAcelyrin Cuts Workforce, Deprioritizes Former Lead Drug IzokibepSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 14, 2024 | seekingalpha.comAcelyrin, Inc. (SLRN) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | ca.finance.yahoo.comInvestors reduced allocations to stocks, moved to cash in August, BofA survey showsAugust 13, 2024 | marketwatch.comAcelyrin to Reduce Workforce by One-Third as Portfolio's Priorities ShiftAugust 13, 2024 | msn.comWhy Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now?August 6, 2024 | globenewswire.comACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024May 29, 2024 | globenewswire.comACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024May 18, 2024 | finance.yahoo.comAcelyrin, Inc. (SLRN)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising PipelineMay 15, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024See More Headlines Receive SLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLRN CUSIPN/A CIK1962918 Webwww.acelyrin.com Phone805-730-0360FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$10.83 High Stock Price Target$20.00 Low Stock Price Target$6.00 Potential Upside/Downside+155.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-381,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.10% Return on Assets-41.46% Debt Debt-to-Equity RatioN/A Current Ratio7.86 Quick Ratio7.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.69 per share Price / Book0.75Miscellaneous Outstanding Shares99,810,000Free Float85,559,000Market Cap$423.19 million OptionableOptionable Beta2.34 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Melanie Gloria B.S.N. (Age 46)Chief Operating Officer Comp: $667.52kMs. Mina Kim (Age 50)CEO & Director Mr. Gilbert M. Labrucherie J.D. (Age 52)CFO & Chief Business Officer Mr. Tyler MarciniakHead of Investor Relations & CommunicationsMs. Sanam Pangali J.D.Chief Legal Officer & Head of PeopleDr. Paul M. Peloso M.D. (Age 66)M.Sc., Chief Medical Officer Ms. Suzy Buckhalter CPASenior Director of Finance & AccountingMr. Kenneth A. Lock (Age 50)Chief Commercial Officer Dr. Shephard Mpofu M.D.Chief Medical OfficerMs. Patricia A. Turney (Age 57)Chief Technical Operations Officer More ExecutivesKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSARecursion PharmaceuticalsNASDAQ:RXRXImmunocoreNASDAQ:IMCRArvinasNASDAQ:ARVNRocket PharmaceuticalsNASDAQ:RCKTView All CompetitorsInsiders & InstitutionsGhisallo Capital Management LLCSold 17,500 shares on 9/4/2024Ownership: 0.018%Point72 Asset Management L.P.Sold 185,958 shares on 8/19/2024Ownership: 0.038%Almitas Capital LLCBought 376,116 shares on 8/16/2024Ownership: 0.380%Blue Owl Capital Holdings LPBought 100,000 shares on 8/15/2024Ownership: 2.955%The Manufacturers Life Insurance Company Bought 4,163 shares on 8/15/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions SLRN Stock Analysis - Frequently Asked Questions How have SLRN shares performed this year? Acelyrin's stock was trading at $7.46 on January 1st, 2024. Since then, SLRN shares have decreased by 43.2% and is now trading at $4.24. View the best growth stocks for 2024 here. How were Acelyrin's earnings last quarter? Acelyrin, Inc. (NASDAQ:SLRN) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.08. When did Acelyrin IPO? Acelyrin (SLRN) raised $540 million in an initial public offering on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share. Who are Acelyrin's major shareholders? Top institutional investors of Acelyrin include Millennium Management LLC (4.69%), Blue Owl Capital Holdings LP (2.95%), Renaissance Technologies LLC (0.40%) and Almitas Capital LLC (0.38%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston. View institutional ownership trends. How do I buy shares of Acelyrin? Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.